Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Literature DB >> 20729866

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Travis K Warren¹, Kelly L Warfield, Jay Wells, Dana L Swenson, Kelly S Donner, Sean A Van Tongeren, Nicole L Garza, Lian Dong, Dan V Mourich, Stacy Crumley, Donald K Nichols, Patrick L Iversen, Sina Bavari.

Abstract

Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30-60 min after infection, protects>60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20729866 DOI： 10.1038/nm.2202

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

18 in total

Review 1. How Ebola and Marburg viruses battle the immune system.

Authors: Mansour Mohamadzadeh; Lieping Chen; Alan L Schmaljohn
Journal: Nat Rev Immunol Date: 2007-07 Impact factor: 53.106

2. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola).

Authors: S P Fisher-Hoch; G S Platt; G H Neild; T Southee; A Baskerville; R T Raymond; G Lloyd; D I Simpson
Journal: J Infect Dis Date: 1985-11 Impact factor: 5.226

3. Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors: B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal: J Infect Dis Date: 1999-02 Impact factor: 5.226

4. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.

Authors: Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Kinola J N Williams; Joan B Geisbert; Anders Leung; Friederike Feldmann; Lisa E Hensley; Heinz Feldmann; Steven M Jones
Journal: J Virol Date: 2008-04-02 Impact factor: 5.103

5. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management.

Authors: S P Fisher-Hoch; G S Platt; G Lloyd; D I Simpson; G H Neild; A J Barrett
Journal: Lancet Date: 1983-11-05 Impact factor: 79.321

6. Ebola haemorrhagic fever: experimental infection of monkeys.

Authors: E T Bowen; G S Platt; D I Simpson; L B McArdell; R T Raymond
Journal: Trans R Soc Trop Med Hyg Date: 1978 Impact factor: 2.184

7. Development and characterization of a mouse model for Marburg hemorrhagic fever.

Authors: Kelly L Warfield; Steven B Bradfute; Jay Wells; Loreen Lofts; Meagan T Cooper; D Anthony Alves; Daniel K Reed; Sean A VanTongeren; Christine A Mech; Sina Bavari
Journal: J Virol Date: 2009-04-15 Impact factor: 5.103

8. Effective post-exposure treatment of Ebola infection.

Authors: Heinz Feldmann; Steven M Jones; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Ute Ströher; Allen Grolla; Mike Bray; Elizabeth A Fritz; Lisa Fernando; Friederike Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal: PLoS Pathog Date: 2007-01 Impact factor: 6.823

9. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Authors: Thomas W Geisbert; Amy C H Lee; Marjorie Robbins; Joan B Geisbert; Anna N Honko; Vandana Sood; Joshua C Johnson; Susan de Jong; Iran Tavakoli; Adam Judge; Lisa E Hensley; Ian Maclachlan
Journal: Lancet Date: 2010-05-29 Impact factor: 79.321

10. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2.

Authors: Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Howard A Young; Pierre Formenty; Elizabeth A Fritz; Tom Larsen; Lisa E Hensley
Journal: J Infect Dis Date: 2007-11-15 Impact factor: 5.226

91 in total

1. Evaluation of perceived threat differences posed by filovirus variants.

Authors: Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal: Biosecur Bioterror Date: 2011-11-09

2. Clinical aspects of Marburg hemorrhagic fever.

Authors: Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal: Future Virol Date: 2011-09 Impact factor: 1.831

3. Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Authors: Kevin B Spurgers; Tim Alefantis; Brian D Peyser; Gordon T Ruthel; Alison A Bergeron; Julie A Costantino; Sven Enterlein; Krishna P Kota; R C Dutch Boltz; M Javad Aman; Vito G Delvecchio; Sina Bavari
Journal: Mol Cell Proteomics Date: 2010-08-11 Impact factor: 5.911

4. Anti-infectives: Post-exposure antisense protection against lethal filoviruses?

Authors: Alexandra Flemming
Journal: Nat Rev Drug Discov Date: 2010-10 Impact factor: 84.694

5. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies.

Authors: Alison E Heald; Patrick L Iversen; Jay B Saoud; Peter Sazani; Jay S Charleston; Tim Axtelle; Michael Wong; William B Smith; Apinya Vutikullird; Edward Kaye
Journal: Antimicrob Agents Chemother Date: 2014-08-25 Impact factor: 5.191